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IL-6 signaling blockade increases inflammation
but does not affect muscle function in the mdx
mouse
Matthew C Kostek1,4*, Kanneboyina Nagaraju2, Emidio Pistilli2,3, Arpana Sali2, San-Huei Lai2, Brad Gordon1
and Yi-Wen Chen2,5*
Abstract
Background: IL-6 is a pleiotropic cytokine that modulates inflammatory responses and plays critical roles in muscle
maintenance and remodeling. In the mouse model (mdx) of Duchenne Muscular Dystrophy, IL-6 and muscle
inflammation are elevated, which is believed to contribute to the chronic inflammation and failure of muscle
regeneration in DMD. The purpose of the current study was to examine the effect of blocking IL-6 signaling on the
muscle phenotype including muscle weakness and pathology in the mdx mouse.
Methods: A monoclonal antibody against the IL-6 receptor (IL-6r mAb) that blocks local and systemic IL-6 signaling
was administered to mdx and BL-10 mice for 5 weeks and muscle function, histology, and inflammation were
examined.
Results: IL-6r mAb treatment increased mdx muscle inflammation including total inflammation score and ICAM-1
positive lumens in muscles. There was no significant improvement in muscle strength nor muscle pathology due to
IL-6r mAb treatment in mdx mice.
Conclusions: These results showed that instead of reducing inflammation, IL-6 signaling blockade for 5 weeks
caused an increase in muscle inflammation, with no significant change in indices related to muscle regeneration
and muscle function. The results suggest a potential anti-inflammatory instead of the original hypothesized
pro-inflammatory role of IL-6 signaling in the mdx mice.
Keywords: IL-6, Muscular dystrophy, Inflammation, Duchenne
Background
A hallmark feature of Duchenne Muscular Dystrophy
(DMD) is chronic inflammation, it occurs within the
muscle of patients and in the mouse model of the dis-
ease (mdx). Several inflammatory factors (cytokines) in-
crease in the muscle including IL-6, TNF-alpha, and IL-
1 beta [1]. Additionally inflammatory cell infiltration is
found in DMD and mdx muscle, the majority of these
cells being macrophages and lymphocytes [2]. And yet,
while the primary protein defect (dystrophin) causes the
disease, it is now believed that the chronic inflammation
in skeletal muscle hinders the repair or regenerative
process that would occur if this inflammation was
reduced [1,3,4]. Indeed, corticosteroids are a current
standard therapy for boys with DMD, which may act by
reducing inflammation. Yet corticosteroid effects are
highly variable, last for a limited period of time, and
have severe adverse side effects [5]. The exact mechan-
ism by which corticosteroids benefit these patients is un-
known and somewhat paradoxical; long term use causes
muscle wasting in most clinical populations except
DMD. If the beneficial effects (e.g. anti-inflammatory) of
corticosteroid use could be realized without the side
effects it could provide a treatment for those with DMD.
As inflammation is seen as a primary contributor to the
disease pathology, identifying the molecular mediators
(e.g. cytokines, inflammatory cells, growth factors) of
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inflammation that are beneficial to muscle repair in
DMD pathology is likely to lead to new treatments.
Several studies have examined the effect of blocking
inflammatory cytokines or depleting inflammatory cells
in mdx and have consistently yielded promising results.
[2,4,6-10]. For example, in a model of T and B cell deple-
tion the scid mouse was recently crossed with the mdx
(scid/mdx) [11]. Scid/mdx mice showed significantly
improved muscle pathology as measured by fibrosis,
muscle necrosis, and TGF-Beta production. Yet, a report
of immune system depletion (RAG2/mdx mouse) pro-
duced no improvement in muscle strength or function
[12]. Paradoxically, reducing inflammation in healthy
animals where muscle damage has occurred is detrimen-
tal to tissue repair [13] and satellite cell activation and
differentiation [14]. Thus it seems a reduction, not ab-
sence of inflammation is ideal. In this regard, specific
mediators and markers of the inflammatory process (e.g.
IL-6) warrant examination in a dystrophic model.
Il-6 is a ubiquitously expressed cytokine that can have
pro and anti-inflammatory effects depending on concen-
tration and the local tissue milieu of immune cells and
cytokines. IL-6 exerts its biological activities through
interaction with specific receptors expressed on the sur-
face of target cells. The receptor complex mediating the
biological activities consists of two distinct membrane-
bound glycoproteins (ligand binding gp80 and non-ligand
binding component gp130). As numerous cells of the
body express the gp130 transmembrane receptor, the ac-
tivity of IL-6 is wide spread. However, the IL-6 receptor is
required for gp130 activation. The IL-6 receptor (IL-6r)
can be found on the cell surface or in soluble form. IL-6
binding to its soluble receptor and then interacting with
the gp130 receptor is known as “trans” signaling and
allows amplification of IL-6 signaling to cells not normally
expressing the specific receptor. The soluble form of the
receptor can also be shed from cells or be expressed by al-
ternative splicing in cells where IL-6r is expressed. Thus
numerous cell / tissue types can be affected. By blocking
the IL-6r binding site, IL-6 cannot activate gp130, which
effectively eliminates most IL-6 signaling throughout the
body. A monoclonal antibody (mAb) for IL-6r has been
successfully used to prevent and reverse Crohn’s disease,
rheumatoid arthritis, and other inflammatory diseases by
suppressing inflammatory events [15-17]. Indeed, our col-
laborators laboratory recently utilized IL-6 blockade
through this same antibody to suppress the muscle pro-
tein degradation of cancer cachexia [18]. And while all of
the mechanistic actions of IL-6 blockade are not yet clear,
it is very likely to reduce systemic and local levels of in-
flammation, possibly affecting growth factor production (i.
e. Insulin like growth factor 1 (IGF1)) and thus tissue
growth and maintenance [19-23]. Indeed, transgenic mice
overexpressing IL-6 suffer from severe muscle atrophy
which can be ameliorated by blockade of IL-6 with IL-6r
antibody [22]. Likewise, in the mdx mouse IL-6 muscle
levels are dramatically elevated, while in age matched
wild-type IL-6 is negligible; indeed, it’s barely detectable
via western blot in wild-type mice [24]. Interestingly,
muscle of wild-type mice, when injured, expresses IL-6 at
a similar level to mdx mice, but control animal IL-6 levels
quickly return to baseline. Thus, increased levels of IL-6
in muscle are a normal response to injury but resting
levels are very low in healthy muscle and very high in mdx
muscle. In humans, acute increases in IL-6 will decrease
circulating IGF1 (muscle growth factor), while chronic
high levels of circulating IL-6 are associated with a
decreased skeletal muscle mass [25,26]. The effect on
IGF1 is likely direct because IL-6 directly affects liver and
muscle IGF1 [27,28]. Finally, primary muscle cell prolif-
eration and differentiation (known to be critical for
muscle growth) are modulated by IL-6 [27,29,30]. Thus
again while some IL-6 is necessary for proper cell func-
tion, chronic high level exposure of IL-6 to muscle cells
seems to be detrimental. Due to the known effect of IL-6r
mono-clonal antibody (mAb) on inflammation, muscle at-
rophy, and the relationship of inflammation to muscle
function in mdx mice as mentioned, it is an ideal candi-
date therapeutic agent to test in the mdx mouse.
In this study, we tested the efficacy of this agent in miti-
gating muscle disease in mdx mice. As IL-6 is likely to have
systemic and local effects, we examined these through dir-
ect (Suppressor of cytokine signaling 3 (SOCS3), Serum
amyloid a (SAA)) and indirect (TNF-alpha, IGF1) targets of
IL-6 signaling in target tissues, liver and muscle. And as
chronically elevated levels of IL-6 have most often been
reported to be detrimental to skeletal muscle health, we
hypothesized that IL-6r mAb treatment will reduce chronic
muscle inflammation and necrosis and improve muscle
function. Additionally, we hypothesize that these thera-
peutic effects will be related to the effect of IL-6 on IGF1
production.
Methods
Experimental protocol
Thirty-two male mice, 16 C57BL/10ScSn-Dm (mdx) and
16 C57BL/10SnJ (BL-10) mice purchased from Jackson
Laboratories were used in this study. Mice arrived at our
laboratory at approximately 4.5 weeks of age and were
acclimatized to their new environment for 3 days. BL-10
and mdx mice were randomly assigned to either IL-6r
mAb or iso-type matched control (Kh-5) injection groups.
To induce tolerance as previously reported for these
drugs, all mice were given an initial bolus injection
(200 mg/kg in 200 μl sterile saline) of either IL-6r mAb or
the Isotype-matched control (Kh-5) in order to avoid neu-
tralizing antibody production [31]. Mice were then given
subcutaneous injections of their corresponding treatment
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(IL-6r mAb or Kh-5), every third day, 5 mg/kg in 200 μl
sterile saline solution for five weeks (8 mice/group and
four groups). The experimental drugs, anti-IL-6r mAb
(clone MR16–1, rat IgG1) or purified rat IgG as control
(KH-5) were a kind gift of (Chugai-Roche Co. Ltd).
Animals were housed at the Veterans Affairs Animal
Research Facility and all protocols were approved by The
Children’s National Medical Center and V.A. IACUC,
Washington, DC. Mice were checked daily for signs of dis-
tress and were maintained on a 12:12-h light–dark cycle
in a low-stress environment (22°C, 50% humidity and low
noise) and given food and water ad libitum. Data collec-
tion of performance measures were performed within
three hours of the end of the active dark cycle (0700).
After final data collection (24 hours after final subcutane-
ous injection), mice were asphyxiated with CO2 and mus-
cles were immediately dissected, washed in PBS, blotted,
weighed and frozen in isopentane cooled with liquid nitro-
gen. All samples were transferred to chilled tubes on dry
ice and stored at -80c until analysis. Diaphragms were
carefully extracted and placed directly in 10% buffered for-
malin for 24 hrs, transferred to 70% ethanol and shipped
to HistoServe inc. (Germantown, MD) for paraffin embed-
ding, cross-sectioning and H&E staining.
Rotarod (RR) Performance was used to assess neuro-
muscular coordination at the conclusion of the study.
All mice underwent 3 days of acclimatization to the
protocol before primary data collection. Mice were
placed on the rod in the identical forward direction, and
then the RR (Life Science Series 8) was started at 0 rpm
and increased to 40 rpm at 0.4 rpm/s, after a 60 second
acclimatization period at 4 rpm. The latency to fall from
the rod was recorded in seconds with a maximum time
of 180 seconds. This procedure was repeated for a total
of six trials (2 trials per day with > 2 hours of rest time
between trials) over three days, and the average of the
trials was used in the data analysis.
Grip Strength Measurements was used to assess muscle
strength, with measures taken after 5 weeks of treatment.
All GSM measures were conducted by one trained investi-
gator. For forelimb strength, holding the mice by the tail,
the front feet were allowed to grip a grate, and then they
were pulled from the grate, generating a force measured
by the force transducer (Columbus Instruments). For hind
limb strength, both front and back feet were allowed to
grip the grate and mice were pulled across the grate. Five
measurements were taken, five days consecutively, with
the first day used as acclimatization and not included in
final data analysis. The average of the measurements was
used in the data analysis.
Histology
To assess histopathologic differences of mice for skeletal
muscle and diaphragm after treatment, standard measures
of fiber diameter, central nucleation, muscle regeneration
and inflammatory cell counts were made, similar to those
suggested for mdx drug trials [32]. To quantify muscle
histology, transverse frozen muscle sections were cut in a
cryostat after partial embedding in OCT. Cryostat sections
(12-μm thick) were cut at the mid-belly of the gastrocne-
mius of at least 2 sections with a minimum of 50 μm of
separation between each section. Sections were stained
with H&E, dehydrated in ethanol washes, rinsed in xylene,
mounted with Permount, and dried overnight. Stained
slides were observed under 400× magnification (Olympus
BX41) with 2 experienced, blinded reviewers randomly
selecting a total of 20 fields per mouse between at least 2
cut sections for analysis. Diaphragm analysis consisted of
identical measures as skeletal muscle though fewer slides
of optimally preserved tissue were available, which
resulted in lower cell counts in the diaphragms. The Infin-
ity Analyze software, 4.4 was used for all analysis. The
total number of fibers was counted using the manual
counting feature in the software for each of the 20 fields.
All cells in the field of view were used in the analysis.
Additionally, total myonuclei, centralized myonuclei, and
regenerating fibers were counted in 15 fields. To distin-
guish inflammation, regenerating fibers, or fibers with
central nucleation standardized criteria were used. Regen-
erating fibers were identified by small caliber, centralized
large nuclei, and basophilic cytoplasm. Fiber diameters
were calculated based on the minimal ‘Feret’s diameter’
[33]. Fibers not otherwise identified as regenerating or in-
flammatory that contained a centralized nuclei were
counted as a centrally nucleated fiber. Finally, an inflam-
matory score was assigned to each field of view and aver-
aged per slide (mouse), based on the number of observed
mononuclear cells: (<5 inflammatory cells = 0, 5–10 in-
flammatory cells = 1, 11–15= 2, and >15 =3). Data were
expressed as absolute cell counts, μm (diameter), or in-
flammation score 0–3. As a global measure of the muscle
damage and repair process (muscle remodeling), we com-
bined the inflammation and regeneration data by first
ranking the scores for these two variables using a rank-
order scale for each mouse. This was based on scores for
regeneration and inflammation for each individual animal.
The rank-order scale allowed us to combine these data
and utilize a non-parametric statistical analysis to compare
between treatment groups and determine a percentage
difference in rankings between treatment groups.
ICAM-1 staining
Frozen mdx muscle (gastrocnemius) sections were cut
in a cryostat as described for histology, (10-μm thick).
Sections were collected on glass slides and air dried for
20 minutes, fixed in acetone/methanol (50/50) and rehy-
drated in PBS. Muscle sections were blocked in 10% HS,
PBST for 1 hour; incubated with primary ICAM1 Ab
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(biotin labeled, Biolegend) 1:100 in blocking solution at
4 degrees overnight and washed three times (10 min-
utes) in PBST. Slides were then incubated with avidin
(HRP, BioLegend) 1:500 in blocking solution for 60 min-
utes at room temperature. Tissue staining was com-
pleted with DAB substrate (Vector labs) according to
the manufacturer’s protocol. DAB reactions were opti-
mized and stopped at 3 minutes with cold tap water.
Sections were dried briefly and covered with aqueous
mounting medium and glass cover slip.
Sections were examined at 400× magnification (Olym-
pus BX41). A trained blinded reviewer conducted ana-
lysis by selecting 20 random fields from the two muscle
sections per mouse. Lumens were scored as positive or
negative for staining, intra-tester reliability was deter-
mined for the one reviewer analyzing six random slides
(Kappa agreement median = 0.93). Total number of
lumens and total number of “positive” lumens were
quantified. Data are reported as mean number of lumens
and positive lumens per mouse. Normalization was con-
ducted by dividing the number of positive lumens by the
number of negative lumens per mouse and then aver-
aging per treatment.
Quantitative RT-PCR
The contralateral (from that used for histology) gastro-
cnemius and an ~30 mg section of liver from each
mouse was used for RNA extraction and subsequent
quantitative real-time PCR analysis. Tissue was homoge-
nized with a Polytron homogenizer in 1 ml of Trizol
(Invitrogen) and RNA was extracted per manufacturer’s
instructions. Isolated RNA pellets were resuspended in
20 μl of DEPC treated water and RNA concentration,
purity, and integrity were examined using 1 μl of RNA
in the Nanodrop 1000 with a subsequent 800 ng of RNA
run in a 1.1% RNase-free agarose gel stained with eth-
idium bromide. Pictures of gels were taken on an UV
imager (BioSpectrum, UVP).
Total RNA (3 ug) was reverse transcribed to cDNA
using oligo dT primer (0.05 ug/μl) and reagents (Super-
script II) from Invitrogen, (CA) and according to manu-
facturers insturctions, cDNA was amplified in triplicate in
SYBRW Green PCR Master Mix (Applied Biosystems, CA)
except for TNF-alpha and IL-10 which were examined
using TaqMan Gene Expression Assays per manufacturers
instructions. The thermal cycling conditions of our ABI
7300 Real-time PCR system include 94°C for 5 minutes,
followed by 40 cycles of amplification at 94°C for 30 sec-
onds, followed by 60°C for 1 minute. Each SYBR Green re-
action contained 20 ng of template cDNA with 75 nM
primer concentration. PCR primers were designed using a
Primer Express program v 1.01 (Applied Biosystems, CA).
Primer sequences used for murine IGF1 were (forward)
5’ CGCTCTGCTTGCTCACCTTCAC 3’, (reverse) 5’
CACTCATCCACAATGCCTGTCTG 3’; SAA (for-
ward) 5’ CTGCAGAAGTGATCAGC 3’, (reverse) 5’ AT
TGTGTACCCTCTCCCC 3’; 36b4 (forward) 5’ GC
AGACAACGTGGGCTCCAAGCAGAT 3’, (reverse) 5’
GGTCCTCCTTGGTGAACACGAAGCCC 3’; SOCS3
(forward) 5’ GATTTCGCTTCGGGACTAGCTC 3’, (re-
verse) 5’ TTGAGGCGCAGGCTGGTG 3’; GAPDH (for-
ward) 5’ GGAGCCAAACGGGTCATCAT 3, (reverse) 5’
TCACGCCACATCTTTCCAGA 3’.
Standard controls were employed for all qRT-PCR
amplifications. Glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) was used as internal control in the muscle
samples while acidic ribosomal phosphoprotein (36b4)
was used for liver samples. The primers were purchased
from Applied Biosystem, CA. All primers were tested for
non-specific amplicons and primer dimers by visualizing
PCR products on 2% agarose gels prior to performing
qRT-PCR, as well as by dissociation curve analysis fol-
lowing the RT-PCR assays. Additionally, no template
controls were checked for each reaction by melting
curve, agarose gel, and ΔRn. Primer, template, PCR
efficiency was checked for each primer pair. The
2^ΔΔCT method was used to determine fold differences
and a t-test was used (P< 0.05) to test statistical
significance.
Data handling and statistical analysis
Results from body weight are reported as means (SD).
All other data are reported as means ± SE. Force produc-
tion is reported in Newtons per gram of body mass
(N/g) and RR is reported as latency to fall in seconds.
Appropriate statistical assumptions (e.g. normality and
variances) were examined before hypothesis testing. Data
analysis comparing IL-6r mAb treated mice was done
independently for mdx and BL-10 mice with two-tailed
independent t-tests for analyzing central nucleation,
inflammation score, fiber diameter, regenerating fibers,
ICAM-1 lumen scores, and qRT-PCR. To examine
muscle remodeling, quantification scores for inflamma-
tion and regeneration were converted to a rank-order
scale, the data was pooled, and a Wilcoxon rank-sum
test compared differences between treated and
untreated mice. To maintain consistency of the inter-
vention with respect to age of mice (the young age of
mdx mice being critical to inflammation), a subset
(n = 5 per group) of mice were tested at baseline to
asses differences amongst treatment groups for RR
and Grip strength, no differences were detected
amongst treatment groups thus all analysis was con-
ducted between groups on data collected at the con-
clusion of the study. The level of significance was set
at P < 0.05 for all analyses. Statistical analyses were
carried out using SPSS software (SPSS Inc., Chicago
IL)., version 18.0.
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Results
All mice completed the IL-6r mAb trial. No adverse
events occurred due to the multiple injections. At baseline,
body weights between groups were similar and increased
as expected over the 5-week trial. No differences were
noted between IL-6r mAb and Kh-5 groups in total body
or gastrocnemius dissection weight. Antibody treatment
resulted in an 11 % greater strength increase (hindlimb) in
IL-6r mAb treated mdx mice compared to Kh-5 treated
mdx mice, though this did not reach statistical significance
(6.5 ± 0.2 N/g versus 5.7 ± 0.3 N/g, P= 0.055). No differ-
ence was found in forelimb strength of mdx IL-6r mAb
treated mice when compared to mdx Kh-5 treated
(P= 0.28, Figure 1). In control mice (BL-10), no differences
were noted between IL-6r mAb and Kh-5 treated mice
(P= 0.53, 0.86 forelimb and hindlimb respectively).
Rotarod
All mice completed RR measures with only one mdx
mouse per group (IL-6 or Kh-5) attaining the 180 s max-
imum measure. In contrast, nine BL-10 mice achieved
the 180 s maximum, five from the IL-6r mAb group and
4 in the Kh-5 group. No significant differences in RR
performance (Figure 2) were noted after treatment be-
tween IL-6r mAb and Kh-5 treated mdx mice (P = 0.43)
or BL-10 (P = 0.32).
Histology
Blinded reviewers analyzed the randomly selected
microscopy fields of H&E stained sections resulting in
approximately 840 and 780 muscle fibers analyzed
respectively for each mdx-IL6r mAb and mdx-Kh5
mouse. For comparison, approximately 600 fibers from
BL-10 mice were examined (Figure 1). There were no
differences between BL-10 treatment groups. Measures
of central nucleation (CN) were not significantly differ-
ent between treated and un-treated mdx mice, though
mdx-IL6r mAb treated mice had 8% (P = 0.27) fewer CN
fibers in skeletal muscle gastrocnemius (Gas) (Table 1).
Inflammation scores were nearly 50% higher in IL-6r
mAb treatment group in skeletal muscle (Gas) as com-
pared to mdx Kh-5 treated mice (P = 0.04). A histogram
of muscle diameters (Figure 3) demonstrates little differ-
ence between IL-6r mAb treated and Kh-5 treated mdx
mice, though IL-6r mAb treated mouse muscle dia-
meters were slightly smaller (Table 1). IL-6r mAb treat-
ment demonstrated no change in the number of
regenerating fibers (P = 0.07) (Table 1). To understand
the muscle damage and regeneration process from a glo-
bal perspective, as IL-6 plays a complex role in the
process of muscle degeneration/regeneration, we com-
bine the inflammation and regeneration scores by first
converting them to a rank-order scale, combining the
two ranks, followed by a Wilcoxon rank-sum test. The
results showed that the pooled variable of muscle re-
modeling increased 37% in IL-6r mAb mdx mice com-
pared to Kh5 treated mdx (P = 0.02).
ICAM1 staining
A total of 20 fields were randomly selected per mouse. A
total of 38 lumens within the skeletal msucle were quan-
tified for Kh-5 treated, and 41 lumens for IL-6r mAb
treated mdx mice. Figure 4 demonstrates the differences
Figure 1 Comparison of grip strength corrected for body weight after IL-6r mAb treatment. Comparison of final grip strength measured in
BL-10 and mdx mice after 4 weeks of IL-6 mAb or control Ab (Kh-5) treatment. T-test comparisons were made between treatment groups.
Asterisk represents difference of (p = 0.055). Data are means and bars represent SEM.
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between mdx-IL-6r mAb treated and mdx-Kh-5 trea-
ted. Figure 5 is representative of a positive versus
negatively stained lumen for ICAM1. When normal-
ized to the number of non-stained lumens, IL-6r
mAb treated mdx had 4 positive lumens to Kh-5’s 1
(P = 0.04).
Real-time PCR
Under optimized conditions for all primer pairs, SAA
mRNA (marker of systemic IL-6 action) levels in the
liver were 3.8 ± 0.4fold lower (P < 0.01) in mdx-IL-6r
mAb treated mice versus mdx-Kh-5 treated mice
(Figure 6). Gastrocnemius muscle SOCS3 (marker of
local IL-6 action, Figure 7) was 2.8 ± 0.5 fold lower
(P = 0.05) and IL-10 was 2.1 ± 0.3 fold higher (P = 0.03)
in mdx-IL-6r mAb treated mice versus mdx-Kh-5 trea-
ted mice (Figure 6). TNF-alpha of treated mdx was not
different from untreated mdx, (1.2 ± 0.5 fold, P = 0.45).
IGF1 mRNA levels were not significantly different be-
tween mdx-IL-6r mAb and mdx-Kh-5 treated mice in
the liver, (1.1 ± 0.1 fold higher in mdx/IL-6r mAb,
P = 0.78) or muscle (1.4 ± 0.3 fold higher in mdx/IL-6r
mAb, P = 0.71, Figures 6 & 7).
Discussion
Here we report the first study to block IL-6 signaling in
mdx mice. We hypothesized that overproduction of IL-6
by mdx muscle contributes to the pathologic inflamma-
tion of the disease and that by reducing IL-6 signaling
we would decrease inflammation and improve muscle
pathology. On the contrary, we report that five weeks of
IL-6 blockade caused an increase in muscle inflamma-
tion, with no change in muscle regeneration. Also con-
trary to our expectations, we found no change in IGF1
gene expression by muscle or liver. And although there
was a trend for improvements in one measure of grip
strength after 5 weeks of IL-6r mAb treatment, no
measures of muscle function reached statistical sig-
nificance. The increase in inflammation is complex
and will require a more specific inquiry into mechan-
isms and consequences than our current study pro-
vides. The modulation of inflammation we observed
could be beneficial (e.g. up-regulation of IL-10) or
detrimental.
Chronic high levels of circulating IL-6 is associated
with muscle wasting in rodents and humans. Exogenous
injections of IL-6 induces skeletal muscle protein
Figure 2 Comparison of rotarod latency to fall time after IL-6r mAb treatment. Comparison of BL-10 and mdx mice after 4 weeks of IL-6
mAb or control Ab (Kh-5) treatment. Data are means and bars represent SEM.
Table 1 Histological analysis of L-6r mAb treated and control (Kh-5) treated mdx and bl/10 mice
Regenerating fibers (n) Diameter (um) Central nucleated fibers (%) Gas Central nucleated fibers (%) Dia Inflamation score
Kh5-mdx 5.6 ± 1.2 34.1 ± 1.0 72.8 ± 2.6 32.8 ± 1.9 14.9 ± 3.4
IL6rab-mdx 9.6 ± 1.7 31.7 ± 1.6 64.5 ± 6.9 29.3 ± 1.4 26.2 ± 3.1
kh5-bI/10 0.4 ± 0.1 38.2 ± 1.1 2.2 ± 0.5 1.8 ± 0.3 1.4 ± 1.2
IL6Ab-bl/10 0.2 ± 0.1 40.1 ± 0.8 1.5 + 0.5 0.9 ± 0.1 3.1 ± 1.1
Data are means and SEM for the gastrocnemius (Gas) unless indicated as diaphragm (Dia).
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breakdown in rats [34] and mice [35]. In addition, skel-
etal muscle growth in young rats is attenuated by
chronic high levels of IL-6 [36]. In terms of disease
states, overexpression of IL-6 can cause cancer cachexia
[37]. In humans, exogenously administered IL-6 up to
high physiologic circulating levels, causes a decrease in
circulating IGF1 [26]. The decrease in IGF1 is likely due
to decreased liver production and this is likely to
attenuate muscle growth. Additionally, in cross-sectional
studies of the elderly, a decrease in muscle (sarcopenia)
correlates with high circulating IL-6 [25]. Yet, while
chronic high levels of IL-6 appear detrimental to muscle,
a complete absence of IL-6 hinders muscle repair.
Knock-out models of IL-6 have shown that it is neces-
sary for proper muscle hypertrophy, activation of satel-
lite cells, and regulation of extracellular matrix
Figure 3 Fiber diameter histogram of mdx mice after 4 weeks of IL-6r mAb or control (Kh-5) treatment. Data are means and bars
represent SEM.
Figure 4 Comparison of lumen counts for ICAM1 staining of gastrocnemius cross-sections. Comparison of mdx mice after 4 weeks of IL-6r
mAb or control Ab (Kh-5) treatment. * indicates P < 0.05. Data are means and bars represent SEM.
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remodeling [38,39]. Thus the IL-6/muscle interaction is
complex but chronic high levels of IL-6, as occurs in the
mdx mouse, is likely detrimental to muscle [24].
Therefore, as chronic inflammation is associated with
muscle loss and reducing inflammation in mdx appears
to be beneficial, we used a compound that blocks a me-
diator of systemic (acute phase response, APR) and
muscle inflammation, IL-6. The IL-6r mAb has been
used successfully to treat several models of inflammatory
diseases [15-17]. In each trial, circulating IL-6 protein
levels are not affected but IL-6 signaling is blocked as
verified by common liver markers of APR such as serum
amyloid A (SAA) expression. Therefore, we verified ef-
fectiveness in our model by examining the immediate
downstream effect of IL-6 signaling systemically (SAA in
liver) and locally (SOCS3 in muscle). Indeed, IL-6r mAb
had an effect both systemically and locally to reduce IL-
6 signaling in mdx mice
Contrary to our primary hypothesis, after 5 weeks of
IL-6r mAb treatment in mdx mice, inflammation
increased. Because IL-6 can increase or exacerbate the
inflammatory process and because mdx mice have ex-
tremely high levels of IL-6 expression in skeletal muscle
along with inflammation, we hypothesized that by de-
creasing IL-6 signaling, inflammation would also de-
crease. Analysis of H&E stained muscle samples found a
nearly 50% increase in inflammation. Yet, H&E stained
samples only estimate inflammation. To examine a more
Figure 5 Representative (+) and (−) stained lumens in mdx gastrocnemius muscle. A) Negatively stained lumen B) positively stained lumen;
(400× magnification). Scale bar: (A) 50 μm.
Figure 6 Gene expression of mdx treated relative to control-Ab treated liver. Insulin like growth factor 1 (IGF1) and serum amyloid A (SAA)
were measured in liver samples of mdx mice treated with IL-6r mAb (blocks IL-6 signaling) or control Ab. Samples are normalized to GAPDH and
the fold change from mdx control mice is presented. Independent t-tests examined statistical differences (* indicates p < 0.05). Data are means
and bars represent SEM.
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direct marker of tissue inflammation we quantified
ICAM-1 as it will be expressed by the vascular endothe-
lium where leukocytes will bind ICAM-1 on the endo-
thelial surface and transmigrate across the vascular
endothelial and into tissues during the inflammatory
process [40,41]. ICAM-1 staining confirmed that an in-
crease in inflammation occurred in our IL-6r mAb trea-
ted mdx mice. As this was contrary to our original
hypothesis and due to the ability of IL-6 to modulate
pro-inflammatory cytokines (TNF-alpha) while not
affecting pro-growth cytokines (TGF-Beta), we sought to
examine markers that are consistently shown to be pro-
inflammatory or pro-growth in skeletal muscle. TNF-
alpha muscle gene expression was not different between
treated and untreated mice while IL-10 muscle gene ex-
pression increased. Thus it is possible that while overall
inflammation increased it could be pro-growth and sup-
port increased regeneration (i.e. # of regenerating fibers),
[42]. Indeed, IL-10 has been shown to be beneficial in
mdx mice [43] and thus may be increasing regeneration,
while no change in TNF-alpha is suggestive that overall
pro-inflammatory signals were not affected by our
treatment.
Our findings in inflammation are not without prece-
dent, in mdx mice, other treatments that should de-
crease inflammation have been shown to cause an
increase of inflammation [7,8]. In our current studies,
this could have been caused by an increase in cytokines
that directly bind to gp130 (e.g. IL-11, IL-27). Further-
more, IL-6 itself can be pro- and anti-inflammatory [44].
It is possible that IL-6 was increased in response to the
high level of inflammation in mdx muscle and that our
treatment was blocking the anti-inflammatory effects of
IL-6. Also as mentioned, the increased level of inflam-
mation may be pro-growth (e.g. 2 C macrophages) as
evidenced by an increase in IL-10. The exact cause or
implication of the increased inflammation is not clear.
Yet, it is seemingly associated with an increase in regen-
erating fibers. And while our measures of regenerating
fibers (H&E) were not statistically different, it was nearly
double when comparing treated to untreated mdx. To
examine this process from a global perspective that
combines the overall damage/inflammation/repair
process, we pooled inflammation and regeneration data
as an indicator of muscle remodeling, and found a sig-
nificant increase occurred due to IL-6 blockade treat-
ment. While the consequences of this increase in
remodeling are unknown, it is likely to have a long term
effect as it is an indication of the overall tissue damage
and repair process including critical aspects of muscle
satellite cell activation. Thus while long-term effects are
not known, IL-6 blockade did cause an increase in
inflammation.
A marker of general muscle growth/repair, IGF1, can
be directly affected by IL-6 levels [26]. As our mAb
treatment should affect cell signaling and thus gene ex-
pression, we used IGF1 mRNA as an indicator of down-
stream consequence of blocking IL-6 signaling and an
indicator of muscle growth. IL-6r mAb did not affect
IGF1 gene expression in muscle or liver of mdx treated
Figure 7 Gene expression of mdx treated relative to control-Ab treated gastrocnemius muscle. Insulin like growth factor (IGF1),
Suppressor of cytokine signaling 3 (SOCS3), Tumor necrosis factor (TNF-alpha), and Interleukin 10 (IL-10) were measured in muscle samples of
mdx mice treated with IL-6r mAb (blocks IL-6 signaling) or control Ab. Samples are normalized to GAPDH and the fold change from mdx control
mice is presented. Independent t-tests examined statistical differences (* indicates p < 0.05). Data are means and bars represent SEM.
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mice. And though IGF1 did not change, the increased
remodeling is suggestive of additional growth factor re-
lease. Indeed, IL-10 did increase due to treatment and it
is possible that other growth factors may have increased
and/or macrophage subtype conversion to a pro-growth
phenotype (M2c) could have occurred which leads to
satellite cell or fibroblast proliferation [45]. Yet, in the
case of fibroblast proliferation in mdx, it is likely to have
detrimental consequences of increased collagen produc-
tion and fibrosis [46]. The current treatment of 5 weeks
is unlikely to produce any definitive results in terms of
fibrosis; a longer study is needed. IGF1 gene expression
was not affected locally or systemically, contrary to our
hypothesis. This suggests that IL-6 was not hindering
this growth pathway.
After 5 weeks of IL-6 signaling blockade in mdx mice
there was no change in measures of muscle function.
And while five weeks is a short period to improve
muscle function, our a-priori calculation of statistical
power should have allowed us to detect a 10% increase
in some measures of muscle function. A post-hoc ana-
lysis of our data revealed a greater variance in our grip
strength data than was used in our a-priori power calcu-
lation, causing a decrease in statistical power. In this re-
gard, though the increase was not statistically significant,
we note a trend for hind-limb grip strength to increase
(11%). The increase in muscle strength, in our data,
could be due to an actual increase in muscle force pro-
duction or could be due to a reduction in body weight
and while our mdx did tend to gain weight at a faster
rate than BL-10 mice (which is typical of mdx) if body
weight is increasing proportionally to the increase in
strength, then functionally or in terms of ambulation, it
would be of little consequence. Also noteworthy of the
muscle strength testing is that testing could in theory
cause muscle damage but we are aware of no reports of
this affecting these measures in mdx mice. Furthermore,
it was recently reported that although susceptible to in-
jury, mdx mice respond to muscle damage by a repair
process that is at least as efficient as BL-10 mice [47].
Our other measure of muscle function, neuromuscular
coordination, could also have been improved by the
reduced inflammation alone, though we found no
change [48,49]. A more precise measure of muscle force
production would have allowed us to detect smaller
changes in muscle function and though this was
attempted on a small number of soleus muscle samples
(ex-vivo) technical difficulties in data collection prohib-
ited analysis of. As improved muscle function could be
caused by increases in size or number of myofibers, a re-
duction in muscle necrosis, or improved muscle repair
we note that dissected muscle weights normalized for
body weight were not different between groups of trea-
ted mice and while muscle fiber counts were greater in
mdx treated mice in randomly selected microscopic
fields, the fiber diameter was less and could account for
the greater number of fibers counted. Thus as remodel-
ing was increased it did not affect standard measures of
muscle function.
The strength of the current study is the well character-
ized therapeutic agent and model of disease (mdx). The
therapeutic agent has been used to treat several inflamma-
tory diseases and blocks nearly all IL-6 signaling through-
out the body and did so in our current investigation
[15-17]. The early life of the mdx mouse (4–12 weeks) is
considered the point of greatest inflammation and muscle
necrosis and is thus an appropriate target age for studies
such as ours [50]. A limitation of our study is having only
one time point (5 weeks) of pathologic analysis. Thus,
short-term effects beyond inflammation are difficult to
interpret in terms of consequences such as fibrosis, lon-
gevity, or long term muscle function. Future studies
should pursue the inflammation by more direct measures,
i.e. cell sorting on fresh tissues, to more precisely quantify
inflammation. Furthermore, a long term study could more
directly address the effects of modified inflammation,
fibrosis, and muscle repair.
Conclusion
The current study showed that while IL-6 signaling is
believed to contribute to the chronic inflammation
and muscle wasting in DMD, reducing IL-6 signaling
using neutralizing antibodies did not reduce the
inflammation in mdx mice. Instead, the inflammation
was increased by the treatment. Considering the
muscle strength and pathology were either slightly
improved or no change, the increase in inflammation
is likely directly in response to the reduction of IL-6
signaling, which implies an anti-inflammatory role of
IL-6 signaling in the mdx mice. In conclusion, while
IL-6 is affecting the muscle inflammation and remod-
eling process in mdx, short term blockade does not
produce statistically significant improvements in dis-
ease pathology or muscle function.
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